List of Excipients in Branded Drug CALCIUM CHLORIDE DIHYDRATE

Generic Drugs Containing CALCIUM CHLORIDE DIHYDRATE

Company	Ingredient	NDC	Excipient
Somerset Therapeutics LLC	calcium chloride dihydrate	70069-773	HYDROCHLORIC ACID
Somerset Therapeutics LLC	calcium chloride dihydrate	70069-773	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in CALCIUM CHLORIDE DIHYDRATE?

# Of NDCs	Excipient
1	HYDROCHLORIC ACID
1	SODIUM HYDROXIDE

Calcium Chloride Dihydrate Excipient Strategy, Patent Landscape, and Commercial Opportunities

Last updated: August 27, 2026

Calcium chloride dihydrate is a low-cost, established inorganic salt used primarily as an active electrolyte in sterile injections and as a process or formulation component in pharmaceutical manufacturing. Its commercial value is driven by grade control, sterility assurance, packaging, supply reliability, and application-specific formulation support rather than molecule-level patent protection. The strongest opportunities are ready-to-use calcium chloride injections, low-endotoxin excipient supply, cell and gene therapy manufacturing inputs, dialysis products, and dual-source supply programs.

Calcium chloride dihydrate has no meaningful new-chemical-entity exclusivity. Commercial differentiation depends on regulatory documentation, validated impurity control, container compatibility, and dosage-form execution.

What is calcium chloride dihydrate used for in pharmaceutical products?

Calcium chloride dihydrate, CAS No. 10035-04-8, has a molecular weight of approximately 147.01 g/mol. It is the dihydrate form of calcium chloride and supplies calcium ions and chloride ions in aqueous formulations.

Its main pharmaceutical uses are:

Use	Function	Commercial relevance
Calcium chloride injection	Active electrolyte and calcium replacement agent	Emergency medicine, hypocalcemia, resuscitation
Parenteral nutrition	Calcium source	Hospital compounding and premix manufacturing
Dialysis and renal products	Electrolyte component	Chronic-use institutional products
Cell culture and bioprocess media	Calcium source or process component	Biologics and advanced-therapy manufacturing
Oral electrolyte formulations	Mineral source	Lower-value, formulation-dependent opportunity
Pharmaceutical processing	Ionic-strength or calcium-control reagent	Contract manufacturing and biologics production

A 10% calcium chloride injection commonly contains 1 g of calcium chloride dihydrate in 10 mL, equivalent to approximately 273 mg of elemental calcium per 10 mL. The elemental-calcium concentration must be stated clearly because calcium chloride products are frequently confused with calcium gluconate products, which deliver substantially less elemental calcium per unit volume.

What FDA regulatory status applies to calcium chloride dihydrate?

Calcium chloride is an established pharmaceutical active ingredient rather than a new molecular entity. Calcium chloride injection products are marketed in the United States as prescription drugs, including sterile injectable products listed in FDA drug-labeling databases and commercial product catalogs.

The regulatory classification depends on the intended use:

Product type	Likely regulatory pathway	Key issue
Calcium chloride injection	NDA, ANDA, or approved legacy product pathway	Sterility, strength, route, labeling, container closure
Pharmaceutical excipient	Generally supported through established-use documentation and drug-product review	Quality, impurity profile, intended concentration
Bioprocess raw material	Manufacturing-material qualification	Endotoxin, bioburden, trace metals, lot consistency
Oral supplement	Food, dietary supplement, or drug pathway depending on claims	Labeling and product classification
Dialysis concentrate	Device or combination-product framework may apply	Electrolyte accuracy and system compatibility

FDA’s Inactive Ingredient Database should be reviewed by route and dosage form before using calcium chloride dihydrate as an excipient. Inclusion in the database can support precedent but does not eliminate the need to justify concentration, route, quality grade, and manufacturing controls in a specific drug application.[1]

What formulations are protected by calcium chloride patents?

The calcium chloride dihydrate molecule is old, widely used, and not a credible target for new composition-of-matter exclusivity. Patent value is more likely to arise from the surrounding product architecture.

Potentially protectable subject matter includes:

• Ready-to-use prefilled syringes
• Premixed calcium chloride solutions
• High-concentration injectable formulations
• Stabilized calcium-containing parenteral nutrition products
• Multicomponent electrolyte systems
• Container-closure systems that limit precipitation or leakage
• Manufacturing processes for low-endotoxin calcium chloride
• Calcium-containing cell-culture or viral-vector media
• Formulations that control pH, osmolality, or precipitation
• Packaging systems designed for emergency-department use
• Device combinations involving autoinjectors or dose-controlled delivery

A formulation patent must claim more than the presence of calcium chloride. Claims are more defensible when they establish a defined concentration range, excipient combination, pH range, container material, stability profile, or manufacturing parameter that produces a measurable technical result.

How strong is the patent estate for calcium chloride dihydrate?

The core patent estate is weak because the active salt and its standard pharmaceutical uses have extensive prior art. The strongest remaining patent positions are narrow and product-specific.

Patent layer	Expected strength	Commercial assessment
Calcium chloride dihydrate composition	Very low	Ancient, widely disclosed substance
Standard calcium chloride injection	Low	Vulnerable to prior-art and obviousness challenges
Specific concentration and dosage form	Low to moderate	Strength depends on unexpected stability or safety results
Prefilled syringe or delivery device	Moderate	May support device or packaging claims
Low-endotoxin manufacturing process	Moderate	Defensible if process parameters produce reproducible quality
Bioprocess media formulation	Moderate to high	Depends on proprietary cell-line or viral-vector performance data
Combination electrolyte formulation	Moderate	Potential value if precipitation and stability are solved
Trade-secret quality system	Moderate	Often more valuable commercially than patents

A freedom-to-operate review should separate patents covering calcium chloride itself from patents covering the final dosage form, delivery device, manufacturing process, and use in a specific biological production platform. Searching only the active ingredient will understate potential risk.

When does calcium chloride dihydrate lose exclusivity?

Calcium chloride dihydrate has no meaningful remaining molecule-level exclusivity timeline. Its commercial protection is already limited to product-specific approvals, trademarks, manufacturing know-how, and any surviving formulation or device claims.

Exclusivity category	Status
U.S. NCE exclusivity	Not applicable
U.S. orphan-drug exclusivity	Not inherent to calcium chloride
U.S. pediatric exclusivity	Product-specific and not inherent to the ingredient
U.S. authorized-generic protection	Product-specific
Orange Book patent protection	Must be assessed against each listed product
Biosimilar exclusivity	Not applicable
Generic entry barrier	Primarily formulation, sterile manufacturing, supply, and regulatory execution

Because calcium chloride is a small molecule and not a biologic, biosimilar rules do not apply. Competitors would generally pursue generic-drug or abbreviated pathways rather than biosimilar approval.

What is the Orange Book status of calcium chloride injection?

The Orange Book status must be evaluated by product, sponsor, dosage form, and application number. Calcium chloride itself does not create a uniform Orange Book position across all manufacturers.

The relevant diligence questions are:

1. Is the product approved under an NDA or ANDA?
2. Does the reference product have listed patents?
3. Are any listed patents expired, delisted, or subject to a Paragraph IV certification?
4. Does the product have a 30-month litigation stay?
5. Is the relevant dosage form a vial, syringe, premix, or another presentation?
6. Does the proposed generic match the reference product’s route and strength?

For a standard injectable calcium chloride product, the principal competitive barrier is usually sterile manufacturing and regulatory comparability rather than patent exclusivity. FDA’s Orange Book and Drugs@FDA should be reviewed together because product-level approval information and patent listings can differ by application.[2,3]

Which companies are challenging calcium chloride injection products?

Generic competition in calcium chloride injection is generally fragmented among hospital injectable manufacturers, contract manufacturers, and specialty pharmaceutical companies. Publicly available evidence of a major, ingredient-wide Paragraph IV campaign is limited.

A Paragraph IV challenge would be commercially relevant only if an identified reference product carried an unexpired listed patent. Potential challengers would likely target:

• A specific ready-to-use syringe
• A proprietary premixed formulation
• A device-enabled product
• A patent covering container compatibility
• A formulation with a narrow stability claim

For standard calcium chloride injection, market entry is more likely to occur through ordinary generic competition, contract manufacturing, or hospital-supply tenders than through high-value patent litigation.

What patent litigation affects calcium chloride dihydrate products?

No ingredient-wide litigation framework controls calcium chloride dihydrate. Litigation exposure is product-specific and should be screened across four categories:

Litigation category	Typical claim
Formulation	Concentration, pH, excipient, precipitation control
Manufacturing	Purification, endotoxin reduction, crystallization, drying
Packaging	Syringe, vial, ampoule, or closure configuration
Method of use	Treatment of hypocalcemia, resuscitation, or specialized clinical use

Settlement agreements are unlikely to create a material market-wide entry date unless a branded product has a surviving formulation or device patent. Any settlement should be examined for licensed entry dates, authorized-generic rights, supply obligations, launch restrictions, and patent-expiration definitions.

What excipient quality attributes matter most?

For injectable use, calcium chloride dihydrate should be managed as a high-risk parenteral raw material. The relevant quality attributes include:

• Assay and identity
• Water content and hydrate state
• Trace metals
• Insoluble matter
• Sulfate and other anionic impurities
• Bioburden
• Bacterial endotoxins
• Particulate burden
• Solution clarity
• pH and osmolality contribution
• Packaging compatibility
• Lot-to-lot concentration consistency

The dihydrate state matters because conversion to anhydrous calcium chloride changes molecular weight and can cause assay errors if manufacturing instructions do not specify the basis of calculation. Hygroscopicity also affects weighing, storage, and packaging.

Calcium salts require strict compatibility control. Calcium can precipitate with phosphate and carbonate under certain conditions. Calcium-containing products also require careful review when administered with ceftriaxone, particularly in neonates, because of the risk of precipitate formation.[4] These constraints create an opportunity for suppliers that provide validated compatibility data rather than only a certificate of analysis.

What manufacturing and IP barriers exist?

The main manufacturing barriers are operational:

1. Producing consistent pharmaceutical-grade material.
2. Controlling endotoxin and bioburden.
3. Preventing moisture uptake during storage.
4. Maintaining hydrate-state consistency.
5. Supporting sterile filtration or terminal sterilization where applicable.
6. Demonstrating compatibility with glass, elastomer, plastic, and syringe components.
7. Securing reliable supply of qualified starting material.
8. Maintaining dual-site or dual-source qualification.

A supplier can create defensible commercial value through a documented platform that includes qualified raw materials, validated drying conditions, controlled particle characteristics, endotoxin reduction, and regulatory support. The strongest trade-secret position may reside in process control and release testing rather than a broad patent.

What commercial opportunities exist for calcium chloride dihydrate?

Ready-to-use emergency injections

Hospitals value products that reduce bedside preparation. Prefilled syringes and unit-dose presentations can command a higher price than bulk vials if they reduce medication errors, preparation time, and waste.

The product opportunity is strongest where the formulation has:

• Clear elemental-calcium labeling
• Low extractables and leachables
• Long room-temperature stability
• Tamper-evident packaging
• Barcode and automated-dispensing compatibility
• Reliable availability during drug shortages

Sterile injectable contract manufacturing

Calcium chloride injection is technically simple but operationally demanding. Contract manufacturers can compete through small-batch flexibility, validated sterile filling, and supply continuity.

Cell and gene therapy manufacturing

Calcium chloride is used in some cell-culture and transfection workflows. The higher-value opportunity is not commodity calcium chloride. It is a qualified, traceable, low-endotoxin material supported by application data for a specific cell line, viral-vector process, or media system.

Dialysis and electrolyte products

Calcium chloride and other calcium salts are used in electrolyte management and dialysis-related products. This segment rewards consistent concentration, validated mixing, and compatibility with automated compounding systems.

Pharmaceutical-grade excipient distribution

Regional distributors can create value by offering smaller pack sizes, temperature- and moisture-controlled logistics, documentation packages, and rapid replacement supply. This is particularly relevant for emerging pharmaceutical manufacturers that cannot economically purchase industrial-scale quantities.

How does calcium chloride compare with calcium gluconate?

Attribute	Calcium chloride dihydrate	Calcium gluconate
Elemental calcium delivery	Higher per gram and per milliliter	Lower
Injection irritation	Greater risk of tissue injury on extravasation	Generally less concentrated
Emergency use	Often selected when rapid calcium delivery is needed	Common alternative depending on clinical setting
Formulation complexity	High chloride and precipitation considerations	Different solubility and concentration constraints
Patent value	Very low at molecule level	Very low at molecule level
Commercial differentiation	Packaging, sterility, concentration, supply	Same, with greater focus on concentration and tolerability

Product selection is clinical and formulation-specific. A calcium chloride product cannot be treated as a direct commercial substitute for calcium gluconate without accounting for elemental calcium, route, concentration, tissue toxicity, and labeling.

What generic launch risks exist?

The generic launch risk is moderate from a manufacturing perspective and generally low from a molecule-patent perspective.

Risk	Impact
Sterile manufacturing failure	High
Container-closure incompatibility	High
Inadequate particulate or endotoxin control	High
Patent blocking a proprietary syringe or premix	Low to moderate
Active-ingredient patent barrier	Very low
Supply-chain interruption	Moderate to high
Hospital purchasing concentration	Moderate
Price erosion after multiple entrants	High

A new entrant should expect pricing pressure for conventional vials. Better economics are more likely in differentiated presentations, shortage-resistant supply, contract manufacturing, or validated bioprocess-grade material.

What are the geographic opportunities?

The United States offers a mature but competitive injectable market. Europe rewards compliance with European Pharmacopoeia standards and centralized documentation. Japan, China, India, and emerging markets offer volume opportunities but may require local registration, local manufacturing, or region-specific pharmacopoeial support.

Geographic strategy should prioritize:

• Countries with recurrent injectable shortages
• Markets with growing hospital infrastructure
• Regions expanding local sterile manufacturing
• Biologics-manufacturing clusters
• Jurisdictions that recognize established pharmacopoeial standards

Patent risk is usually lower than regulatory and supply-chain risk outside the United States. Local approval requirements and import controls remain material barriers.

Key Takeaways

• Calcium chloride dihydrate is an established inorganic salt with negligible molecule-level patent exclusivity.
• Its primary pharmaceutical role is as an active calcium source, especially in sterile injectable products.
• Excipient opportunities depend on grade, endotoxin control, hydrate-state consistency, documentation, and supply reliability.
• The most valuable patent positions concern formulations, syringes, packaging, manufacturing processes, and bioprocess applications.
• Standard calcium chloride injections face low active-ingredient patent risk but high sterile-manufacturing and price-erosion risk.
• Ready-to-use syringes, hospital premixes, dialysis products, and qualified cell- and gene-therapy raw materials offer the strongest commercial opportunities.
• Calcium chloride is not subject to biosimilar competition; competitors generally use generic-drug or product-specific pathways.
• Orange Book and Paragraph IV analysis must be conducted by reference product and application, not by ingredient alone.

FAQs

Is calcium chloride dihydrate an excipient or an active pharmaceutical ingredient?

It can be either. In calcium replacement injections, it is the active ingredient. In bioprocess media, electrolyte systems, and certain formulations, it can function as a process component or excipient.

Can calcium chloride dihydrate receive a new composition-of-matter patent?

A broad composition patent is commercially unrealistic because calcium chloride dihydrate is an old and extensively disclosed compound. Narrow patents may cover a specific formulation, process, device, or application.

Is calcium chloride dihydrate suitable for injectable formulations?

Yes, provided the material and final product meet applicable compendial, sterility, endotoxin, particulate, assay, and container-closure requirements. Calcium-specific precipitation and extravasation risks require formulation and labeling controls.

What is the best premium strategy for a calcium chloride supplier?

The strongest strategy is to sell a qualified pharmaceutical-grade platform with low-endotoxin performance, controlled hydrate state, validated packaging, regulatory support, and dual-source continuity rather than an undifferentiated commodity salt.

Does calcium chloride dihydrate have biosimilar risk?

No. Calcium chloride is a small inorganic molecule, not a biologic. Competitive entry is governed by generic-drug, product-approval, manufacturing, and procurement dynamics.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
4. DailyMed. (n.d.). Calcium chloride injection labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/